Dow Jones, S&P, Nasdaq, Wall Street Futures Inch Higher as Market Digests Earnings; Intel, Centene Sink, Deckers Jumps

U.S. stock futures ticked up Friday morning, supported by a mostly upbeat earnings season even as several major names posted sharp premarket moves. Investors are also turning their attention to the Federal Reserve’s upcoming policy meeting next week.

Here’s a rundown of the key premarket movers:

  • Intel (NASDAQ:INTC) plunged 8% after the chipmaker projected a larger-than-anticipated loss for the third quarter. It also revealed a significant restructuring plan that includes cutting its workforce by 22%—bringing total headcount to about 75,000 by year-end—via attrition and other cost-cutting measures.
  • Centene (NYSE:CNC) tumbled 13% after posting an unexpected quarterly loss. Elevated healthcare costs related to its insurance operations weighed heavily on the results.
  • Deckers Outdoor (NYSE:DECK) surged 12% as the company delivered a blowout quarter, with strong demand for its Hoka and Ugg brands driving better-than-expected revenue.
  • Phillips 66 (NYSE:PSX) rose 0.6% after the energy company beat Wall Street’s Q2 earnings estimates, aided by improved refining margins and reduced turnaround costs.
  • Charter Communications (NASDAQ:CHTR) slid 7.6% after reporting weaker-than-expected second-quarter earnings. Continued subscriber losses remain a headwind for the cable and broadband provider.
  • Newmont (NYSE:NEM) gained 1.9% as the mining heavyweight topped consensus forecasts for the quarter, thanks to stronger gold prices and operational efficiency.
  • Paramount Global (NASDAQ:PARA) rose 1.1% after U.S. regulators approved its $8 billion merger with Skydance Media, clearing a critical regulatory milestone.
  • Boyd Gaming (NYSE:BYD) added 0.8% after beating Q2 expectations on both earnings and revenue. The company cited solid demand among core players and improved trends in retail gaming.
  • Sarepta Therapeutics (NASDAQ:SRPT) dropped 10% after European authorities issued a negative opinion on its Elevidys gene therapy for Duchenne muscular dystrophy, a major blow to the biotech firm.

With big tech earnings and the Fed decision looming, markets are bracing for a pivotal week. For now, futures on the Dow, S&P 500, and Nasdaq 100 all point to a slightly firmer open.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.


Posted

in

,

by

Tags: